Dr. Nicholas B. Argento

Robert Vigersky is an Endocrinologist in Bethesda, Maryland. Dr. Vigersky is rated as a Distinguished provider by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Low Blood Sugar, Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and Maturity Onset Diabetes of the Young.

Dr. Donner's clinical and research interests have focused on the prevention of complications in patients with type 1 and 2 diabetes. For 6 years, he was the Associate Medical Director of the Joslin Diabetes Center affiliate at the University of Maryland, and then Medical Director from 2004 - 2010. After joining the faculty at Johns Hopkins University in 2010, his clinical and research interests became fully dedicated to diabetes. He became the Director of The Johns Hopkins Diabetes Center in 2011. He has been a clinical investigator in a number of NIH- and industry-funded diabetes research trials. Dr. Donner was a co-PI in the NIH-funded Veterans Affairs Implantable Insulin Pump Study, a Co-PI on the NIDDK-funded Diabetes Control and Complications Trial / Epidemiology of Diabetes Intervention and Complications (DCCT / EDIC) Study for 16 years, and Co-PI for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) for 7 years. Recently, he has served as PI for the Durable-response therapy Evaluation For Early or New-onset type 1 Diabetes (DEFEND-1). Dr. Donner is currently collaborating with Dr. Abdel Hamad in Immunology on preventing B-regulatory cell apoptosis using a novel monoclonal antibody targeting the presumptive apoptotic factor. This antibody prevents the development of type 1 diabetes in non obese diabetic mice. Dr. Donner is the PI for Johns Hopkins for TrialNet, a multicenter, international consortium of investigators studying ways to prevent Type 1 diabetes and preserve insulin secretion in individuals with newly diagnosed Type 1 diabetes. He is also a PI for a study investigating FIAsp, a faster-acting insulin aspart in subjects with type 1 diabetes, and is working with investigators at the Johns Hopkins School of Engineering on an implantable insulin pump which delivers insulin intravenously. Dr. Donner is rated as an Advanced provider by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Type 1 Diabetes (T1D), Diabetic Nephropathy, Type 2 Diabetes (T2D), and Maturity Onset Diabetes of the Young.

Dr. Mathioudakis, an endocrinologist and researcher, has a strong focus on diabetes management and patient care, recognized through awards like the Baltimore Top Doc. He has contributed significantly to diabetes research, authoring over 150 publications and participating in the development of consensus guidelines in the field. His studies have offered valuable insights into using health informatics for diabetes prevention and management. After graduating from the Johns Hopkins University School of Medicine and completing his training in Internal Medicine and a fellowship in Endocrinology, Diabetes, & Metabolism, Dr. Mathioudakis joined the faculty in the Division of Endocrinology, Diabetes & Metabolism in 2012. He earned a Master of Health Science in clinical investigation in 2015 and was the Clinical Director of the Division of Endocrinology from 2016 to 2021. Currently, he co-directs the Baltimore Metropolitan Diabetes Regional Partnership, focusing on improving access to diabetes prevention and management programs. As a physician-scientist, Dr. Mathioudakis leads multiple research studies funded by the NIH, private philanthropic organizations (Helmsley Charitable Trust), non-profit organizations (Breakthrough T1D), and industry. His research focuses on the effectiveness of automated diabetes prevention programs and strategies to reduce racial disparities in diabetes technology access. He also collaborates nationally to enhance care for people with type 1 diabetes. Holding a joint appointment in the Division of Biomedical Informatics and Data Science, Dr. Mathioudakis integrates machine learning and AI in diabetes research. He has served on the national Epic Endocrinology Specialty Steering Board and chaired the Type 2 Diabetes Prognostics Working Group for the Precision Medicine Diabetes Initiative. Committed to education, he frequently lectures on endocrinology, epidemiology, and health informatics. Dr. Mathioudakis is rated as an Advanced provider by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), Low Blood Sugar, Maturity Onset Diabetes of the Young, and Pancreaticoduodenectomy.